BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27737537)

  • 1. Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy.
    Kim HJ; Suh YG; Lee YC; Lee SK; Shin SK; Cho BC; Lee CG
    Cancer Res Treat; 2017 Jul; 49(3):669-677. PubMed ID: 27737537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.
    Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
    Suh YG; Lee IJ; Koom WS; Cha J; Lee JY; Kim SK; Lee CG
    Jpn J Clin Oncol; 2014 Jun; 44(6):534-40. PubMed ID: 24771865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
    Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
    Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012.
    Brower JV; Chen S; Bassetti MF; Yu M; Harari PM; Ritter MA; Baschnagel AM
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):985-993. PubMed ID: 27869098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome.
    Hurmuzlu M; Monge OR; Smaaland R; Viste A
    Dis Esophagus; 2010 Apr; 23(3):244-52. PubMed ID: 19664075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
    Zhu HT; Ai DS; Tang HR; Badakhshi H; Fan JH; Deng JY; Zhang JH; Chen Y; Zhang Z; Xia Y; Guo XM; Jiang GL; Zhao KL
    World J Gastroenterol; 2017 Jan; 23(3):540-546. PubMed ID: 28210091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation field size and dose determine oncologic outcome in esophageal cancer.
    Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
    World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
    Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.
    Lai X; Gu Q; Zheng X; Liu G; Feng W; Lin X; Mao W
    J Cancer Res Ther; 2016 Oct; 12(Supplement):89-95. PubMed ID: 27721263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
    Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
    Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
    Higuchi K; Komori S; Tanabe S; Katada C; Azuma M; Ishiyama H; Sasaki T; Ishido K; Katada N; Hayakawa K; Koizumi W;
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):872-9. PubMed ID: 24867539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.
    Ishikura S; Nihei K; Ohtsu A; Boku N; Hironaka S; Mera K; Muto M; Ogino T; Yoshida S
    J Clin Oncol; 2003 Jul; 21(14):2697-702. PubMed ID: 12860946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Esophageal cancer: outcome according to therapeutic strategy].
    Rousseau D; Capitain O; Denis F; Girault S; Poirier AL; Paumier A; Cellier P; Hamy A; Mahé MA; Mesgouez-Nebout N
    Cancer Radiother; 2013 Feb; 17(1):10-20. PubMed ID: 23270680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of radiotherapy, chemotherapy and surgery in multimodal treatment of locally advanced esophageal cancer.
    Berger B; Stahlberg K; Lemminger A; Bleif M; Belka C; Bamberg M
    Oncology; 2011; 81(5-6):387-94. PubMed ID: 22269965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer.
    Freilich J; Hoffe SE; Almhanna K; Dinwoodie W; Yue B; Fulp W; Meredith KL; Shridhar R
    Dis Esophagus; 2015; 28(4):352-7. PubMed ID: 24635657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience.
    Wang S; Liao Z; Chen Y; Chang JY; Jeter M; Guerrero T; Ajani J; Phan A; Swisher S; Allen P; Cox JD; Komaki R
    J Thorac Oncol; 2006 Mar; 1(3):252-9. PubMed ID: 17409865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.